A5085791905- Platelet Disorders and Treatments
- Blood groups and transfusion
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments
- Renal Diseases and Glomerulopathies
- Histiocytic Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Clinical Laboratory Practices and Quality Control
- Vascular Malformations and Hemangiomas
- Autoimmune Bullous Skin Diseases
- Acute Myeloid Leukemia Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Hemophilia Treatment and Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Research on Leishmaniasis Studies
- DNA Repair Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Parasites and Host Interactions
- Kawasaki Disease and Coronary Complications
- Genetic Syndromes and Imprinting
- Neutropenia and Cancer Infections
- Complement system in diseases
- Blood properties and coagulation
- Phytoplasmas and Hemiptera pathogens
- Escherichia coli research studies
University Children’s Hospital Basel
2009-2024
University of Basel
2018-2024
Boston Children's Hospital
2013-2014
University Hospital of Basel
2005
Abstract Comparative clinical studies of children and adults with immune thrombocytopenia (ITP) are poorly covered in the literature. However, accepted classification ITP—childhood ITP adult ITP—results considerable differences treatment protocols practice guidelines. The analysis Pediatric Adult Registry on Chronic (PARC‐ITP) patients at first presentation demonstrated fewer laboratory findings initial diagnosis between than expected. present report 2‐year follow‐up data supports hypothesis...
Previous guidelines for the treatment of immune thrombocytopenia (ITP) have traditionally focused on a dichotomy between pediatric and adult ITP. Adolescents young adults (AYAs) do not neatly fit into either or ITP group. A deeper understanding ITP’s natural history, risk factors chronicity, outcomes in AYAs is crucial first step toward developing tailored algorithms. Such data could form basis recommendations targeting this underrepresented yet clinically distinct population. Ultimately,...
Abstract Primary immune thrombocytopenia (ITP) in children is a diagnosis of exclusion, but cases secondary ITP and nonimmune (non-IT) are generally difficult to recognize timely fashion. We describe pediatric population with revised or non-IT within 24 months follow-up. Data were extracted from the Pediatric Adult Registry on Chronic ITP, an international multicenter registry collecting data prospectively patients newly diagnosed primary ITP. Between 2004 2019, total 3974 aged 3 16 years...
Transient myeloproliferative disorder (TMD) is a clonal proliferation of megakaryoblasts, typically occurring in newborns with Down syndrome. It believed that TMD occurs the presence GATA1 mutation together trisomy 21. However, limited number patients but without syndrome have been reported, all blast population numeric or rarely structural chromosome 21 abnormalities. We present first case newborn boy and any mentioned molecular cytogenetic This report suggests unknown disease mechanisms...
Immune thrombocytopenia refractory to multiple thrombopoietin receptor agonists remains a challenging clinical problem. This commentary discusses and contextualizes the recent report on this entity from Moulis colleagues, how move forward with these patients. Commentary on: et al. Difficult-to-treat primary immune in adults: Prevalence burden. Results CARMEN-France Registry. Br J Haematol 2024;204:1476-1482.
Current immune thrombocytopenia (ITP) guidelines target children and adults, leading to oversimplification. Adolescents young adults (AYAS) comprise a separate group with distinct health psychosocial issues. This study aimed describe the clinical presentation therapeutic strategies of ITP among AYAS. We analyzed data from two large registries (PARC-ITP; CARMEN-France) included newly diagnosed patients (aged 12–25 years) an initial platelet counts <100×109/L. Patients secondary or...
Summary Defining immune thrombocytopenia (ITP) in two age groups—children and adults—overlooks the specific clinical features needs of adolescents young adults (AYAS). We previously reported a high risk chronic disease at 12 months (50%); however, data on course ITP, refractoriness treatment strategies AYAS are limited. Data from patients aged 12–25 years with primary ITP were extracted three large registries between 2004 2021. Clinical laboratory evaluated until 48 follow‐up (FU)....
Leishmaniasis is endemic in many countries worldwide, with a prevalence of 12 million people infected, and an estimated annual incidence 500 000 visceral leishmaniasis cases. In Europe considered mainly the Mediterranean cases non-endemic European north Alps have primarily been reported returning travellers. The incubation period typically described between 6 weeks to months. presented highlight occurrence longer periods illustrate individual variability for progression from infection...
Summary Thrombopoietin receptor agonists (TPO‐RAs) stimulate platelet production, which might restore immunological tolerance in primary immune thrombocytopenia (ITP). The iROM study investigated romiplostim's immunomodulatory effects. Thirteen patients (median age, 31 years) who previously received first‐line treatment romiplostim for 22 weeks, followed by monitoring until week 52. In addition to data, secondary end‐points included the sustained remission off‐treatment (SROT) rate at 1...
Langerhans cell histiocytosis (LCH) is a rare disease characterized by dysregulated proliferation of myeloid marrow progenitors and subsequent organ infiltration. While LCH associated with favorable prognosis, some survivors may develop chronic health conditions (CHC) because the disease. In this study, we aimed to assess spectrum prevalence CHC among compared siblings identify factors development CHC. The Swiss Childhood Cancer Survivor Study sent questionnaires all ≥ 5-year registered in...
Adolescents and young adults (AYAs) with immune thrombocytopenia (ITP) exhibit distinct clinical features needs, defying categorization as either or children. Previous findings revealed a 50% risk of chronic disease at 12 months, yet the long-term course remains unclear. This study aimed to delineate laboratory characteristics AYAs primary ITP. Data from patients aged 12-25 years 1 year were extracted three registries (PARC-ITP, CEREVANCE, CARMEN), covering period 2004 2021. Sustained...